Completed OBSERVATIONAL NCT04184947

Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists

Cardiovascular Outcomes of Type 2 Diabetic Patients Treated With SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists in Real-life. An Observational Study Using Clinical-administrative Data

Sponsor: University of Padova

Conditions Type 2 Diabetes

Interventions GLP-1 receptor agonist SGLT2 inhibitor

Updated 6 times since 2020 Last updated: Mar 8, 2020 Started: Mar 1, 2014 Primary completion: Dec 31, 2018 Completion: Feb 29, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Type 2 Diabetes, this trial is completed. The trial is conducted by University of Padova and has accumulated 6 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Apr 2020 — Jan 2021 [monthly]

Completed

▶ Show 1 earlier version

Jan 2020 — Apr 2020 [monthly]

Completed

First recorded

Mar 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Padova

Data source: University of Padova

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Padua, Italy